

MASH Diagnostics Market - 2026-2035

<https://marketpublishers.com/r/M94505329AB4EN.html>

Date: June 2026

Pages: 42

Price: US\$ 3,400.00 (Single User License)

ID: M94505329AB4EN

Abstracts

MASH Diagnostics Market reached US\$ 1.41 Billion in 2025 and is expected to reach US\$ 7.72 billion by 2035, growing with a CAGR of 23.94% during the forecast period 2026-2035.

The MASH Diagnostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A MASH Diagnostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Diagnostic Workflow Stage

Initial Screening Methods*

Liver Function Tests

ALT Testing

AST Testing

Platelet Count

Ultrasound Screening

Primary Care Risk Screening

Diabetes Screening Based Liver Assessment

Obesity Risk Based Screening

Metabolic Syndrome Screening

MASH Confirmation Methods

Liver Biopsy

MRI PDFF

Magnetic Resonance Elastography

FibroScan Confirmation

Histopathology Confirmation

Biomarker Based Confirmation

Combined Imaging and Biomarker Confirmation

Fibrosis Staging Methods

FIB 4 Score

NAFLD Fibrosis Score

Enhanced Liver Fibrosis Test

FibroScan

APRI Score

Liver Biopsy Staging

Histological Fibrosis Grading

Others

Treatment Monitoring Methods

ALT Monitoring

AST Monitoring

FibroScan Follow Up

MRI PDFF Follow Up

Biomarker Monitoring

Repeat Liver Function Testing

Disease Regression Tracking

Disease Progression Surveillance Methods

Fibrosis Monitoring

Cirrhosis Risk Tracking

Repeat Imaging Assessment

Liver Function Monitoring

Hepatology Follow Up

Longitudinal Biomarker Tracking

Emerging Diagnostic Technologies

AI Based Risk Scoring

AI Imaging Interpretation

Multomics Diagnostics

Genomic Risk Profiling

RNA Biomarkers

Digital Pathology

Predictive Analytics Platforms

Companion Diagnostics

By Diagnostic Method

Imaging Diagnostics*

Ultrasound

FibroScan

MRI PDFF

Magnetic Resonance Elastography

CT Imaging

Contrast Enhanced Imaging

Blood Based Diagnostics

Liver Enzyme Tests

ALT and AST

Enhanced Liver Fibrosis Test

FIB 4 Index

NAFLD Fibrosis Score

Cytokeratin 18 Biomarkers

Inflammatory Biomarkers

Lipid Profile Markers

Others

Histopathology Diagnostics

Liver Biopsy

Histological Grading

Fibrosis Scoring

Tissue Based Biomarker Analysis

Molecular Diagnostics

RNA Biomarkers

DNA Biomarkers

Genomic Panels

Multomics Diagnostics

Precision Biomarker Panels

AI Enabled Diagnostics

AI Imaging Algorithms

Automated Fibrosis Scoring

Predictive Risk Models

Digital Liver Pathology

By Diagnostic Purpose

Screening Diagnostics*

Disease Confirmation Diagnostics

Fibrosis Staging Diagnostics

Therapy Eligibility Diagnostics

Companion Diagnostics

Treatment Monitoring Diagnostics

Disease Surveillance Diagnostics

Progression Tracking Diagnostics

By Disease Severity

MASLD*

Early MASH

Mild Fibrosis

Moderate Fibrosis

Advanced Fibrosis

Severe Fibrosis

Cirrhosis Stage

High Risk Progression Population

By End-User

Hospitals*

Hepatology Clinics

Gastroenterology Clinics

Diagnostic Laboratories

Imaging Centers

Specialty Liver Centers

Academic Research Centers

Ambulatory Diagnostic Centers

Regional Analysis for MASH Diagnostics Market:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

Go-to-market Strategy.

Neutral perspective on the market performance.

Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

Customized regional/country reports as per request and country level analysis.

Potential & niche segments and regions exhibiting promising growth covered.

Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global MASH Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Data
 - 1.1.1. Secondary Data
 - 1.1.2. Primary Data
 - 1.1.3. CAGR Analysis
- 1.2. Market Size Estimation Methodology
 - 1.2.1. Bottom-Up Approach
 - 1.2.2. Top-Down Approach
- 1.3. Market Breakdown & Data Triangulation
- 1.4. Research Assumptions
- 1.5. Limitations

2. DEFINITION AND OVERVIEW

- 2.1. Study Objectives
- 2.2. Market Definition
- 2.3. Market Scope
- 2.4. Stakeholder Analysis
- 2.5. Currency Considered
- 2.6. Study Period

3. EXECUTIVE SUMMARY

- 3.1. Key Takeaways
- 3.2. Top To Bottom Analysis
- 3.3. Market Share Analysis
- 3.4. Data Points from Key Primary Interviews
- 3.5. Data Points from Key Secondary Databases
- 3.6. Market Snapshot
- 3.7. Geographical Snapshot

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Shift From Biopsy Toward Non-invasive Fibrosis Assessment Is Accelerating

Adoption

4.1.1.2. Metabolic-risk Screening Is Shifting MASH Diagnosis from Hepatology Clinics to Primary Care and Diabetes Care

4.1.1.3. Fibrosis Staging Is Becoming the Key Decision Layer in MASH Diagnostic Workflows

4.1.2. Restraints

4.1.2.1. Advanced imaging and specialty tests remain unevenly accessible across regions

4.1.2.2. Indeterminate fibrosis scores are creating diagnostic uncertainty and referral burden

4.1.3. Impact Analysis - Drivers and Restraints

4.1.4. Opportunity

4.1.4.1. AI enabled imaging and pathology can improve diagnostic confidence and workflow speed

4.1.4.2. Second-line blood biomarker adoption can unlock fibrosis assessment where imaging capacity is limited

4.1.5. Trends

4.1.5.1. Metabolic Disease Surge and GLP-1 Adoption Are Expanding the MASH Diagnostic Funnel

4.1.5.2. Therapy Approvals Are Repositioning MASH Diagnostics as a Treatment Access Gatekeeper

4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis

5.2. Political Factors

5.3. Social Factors

5.3.1. Rising awareness of metabolic health, obesity-linked liver complications and diabetes-associated liver risk is increasing demand for early MASH screening among high-risk patient groups.

5.3.2. Growing patient preference for non-invasive diagnostics is supporting wider adoption of imaging, blood-based biomarkers and fibrosis scoring tools as alternatives to repeated liver biopsy.

5.3.3. Increasing physician focus on early liver disease detection is strengthening diagnostic referrals from endocrinology, gastroenterology, hepatology and primary care settings.

5.4. Economic Factors

5.4.1. Rising healthcare costs associated with advanced fibrosis, cirrhosis, liver failure

and transplant care are driving investment in earlier MASH diagnosis and disease progression monitoring.

5.4.2. Increasing payer and hospital focus on risk stratification is creating demand for cost-effective diagnostic workflows that identify therapy-eligible patients before severe liver damage develops.

5.4.3. Growing pharmaceutical investment in MASH drug development is expanding the need for diagnostic tools that support patient screening, fibrosis staging, trial enrollment and treatment response monitoring.

5.5. Geopolitical Factors

5.6. Supply/Value Chain Analysis

5.7. Pricing Analysis

5.8. Regulatory Analysis

5.9. Technology Landscape

5.10. Innovation & R&D Trends

5.11. Sustainability and ESG Analysis

5.12. Risk Avoidance Model

5.13. Go-To-Market (GTM) Strategy

5.14. BCG Matrix

5.15. Business Models Analysis

5.16. Demand-Supply Gap

5.17. Risk Mitigation Framework

5.18. Compliance Roadmap

5.19. Strategic Implications

5.20. Emerging Opportunities

5.21. Adoption Trends

5.22. Disruption Analysis

5.23. DMI Opinion

6. BY DIAGNOSTIC WORKFLOW STAGE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Workflow Stage

6.1.2. Market Attractiveness Index, By Diagnostic Workflow Stage

6.2. Initial Screening Methods*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.2.3. Liver Function Tests

6.2.3.1. ALT Testing

- 6.2.3.2. AST Testing
- 6.2.4. Platelet Count
- 6.2.5. Ultrasound Screening
- 6.2.6. Primary Care Risk Screening
- 6.2.7. Diabetes Screening Based Liver Assessment
- 6.2.8. Obesity Risk Based Screening
- 6.2.9. Metabolic Syndrome Screening
- 6.3. MASH Confirmation Methods
 - 6.3.1. Liver Biopsy
 - 6.3.2. MRI PDFF
 - 6.3.3. Magnetic Resonance Elastography
 - 6.3.4. FibroScan Confirmation
 - 6.3.5. Histopathology Confirmation
 - 6.3.6. Biomarker Based Confirmation
 - 6.3.7. Combined Imaging and Biomarker Confirmation
- 6.4. Fibrosis Staging Methods
 - 6.4.1. FIB 4 Score
 - 6.4.2. NAFLD Fibrosis Score
 - 6.4.3. Enhanced Liver Fibrosis Test
 - 6.4.4. FibroScan
 - 6.4.5. Magnetic Resonance Elastography
 - 6.4.6. APRI Score
 - 6.4.7. Liver Biopsy Staging
 - 6.4.8. Histological Fibrosis Grading
 - 6.4.9. Others
- 6.5. Treatment Monitoring Methods
 - 6.5.1. ALT Monitoring
 - 6.5.2. AST Monitoring
 - 6.5.3. FibroScan Follow Up
 - 6.5.4. MRI PDFF Follow Up
 - 6.5.5. Biomarker Monitoring
 - 6.5.6. Repeat Liver Function Testing
 - 6.5.7. Disease Regression Tracking
- 6.6. Disease Progression Surveillance Methods
 - 6.6.1. Fibrosis Monitoring
 - 6.6.2. Cirrhosis Risk Tracking
 - 6.6.3. Repeat Imaging Assessment
 - 6.6.4. Liver Function Monitoring
 - 6.6.5. Hepatology Follow Up

- 6.6.6. Longitudinal Biomarker Tracking
- 6.7. Emerging Diagnostic Technologies
 - 6.7.1. AI Based Risk Scoring
 - 6.7.2. AI Imaging Interpretation
 - 6.7.3. Multiomics Diagnostics
 - 6.7.4. Genomic Risk Profiling
 - 6.7.5. RNA Biomarkers
 - 6.7.6. Digital Pathology
 - 6.7.7. Predictive Analytics Platforms
 - 6.7.8. Companion Diagnostics
 - 6.7.9. Others

7. BY DIAGNOSTIC METHOD

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
 - 7.1.2. Market Attractiveness Index, By Diagnostic Method
- 7.2. Imaging Diagnostics*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 7.2.3. Ultrasound
 - 7.2.4. FibroScan
 - 7.2.5. MRI PDFF
 - 7.2.6. Magnetic Resonance Elastography
 - 7.2.7. CT Imaging
 - 7.2.8. Contrast Enhanced Imaging
- 7.3. Blood Based Diagnostics
 - 7.3.1. Liver Enzyme Tests
 - 7.3.1.1. ALT and AST
 - 7.3.2. Enhanced Liver Fibrosis Test
 - 7.3.3. FIB 4 Index
 - 7.3.4. NAFLD Fibrosis Score
 - 7.3.5. Cytokeratin 18 Biomarkers
 - 7.3.6. Inflammatory Biomarkers
 - 7.3.7. Lipid Profile Markers
 - 7.3.8. Others
- 7.4. Histopathology Diagnostics
 - 7.4.1. Liver Biopsy
 - 7.4.2. Histological Grading

- 7.4.3. Fibrosis Scoring
- 7.4.4. Tissue Based Biomarker Analysis
- 7.5. Molecular Diagnostics
 - 7.5.1. RNA Biomarkers
 - 7.5.2. DNA Biomarkers
 - 7.5.3. Genomic Panels
 - 7.5.4. Multiomics Diagnostics
 - 7.5.5. Precision Biomarker Panels
 - 7.5.6. Others
- 7.6. AI Enabled Diagnostics
 - 7.6.1. AI Imaging Algorithms
 - 7.6.2. Automated Fibrosis Scoring
 - 7.6.3. Predictive Risk Models
 - 7.6.4. Digital Liver Pathology

8. BY DIAGNOSTIC PURPOSE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Purpose
 - 8.1.2. Market Attractiveness Index, By Diagnostic Purpose
- 8.2. Screening Diagnostics*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Disease Confirmation Diagnostics
- 8.4. Fibrosis Staging Diagnostics
- 8.5. Therapy Eligibility Diagnostics
- 8.6. Companion Diagnostics
- 8.7. Treatment Monitoring Diagnostics
- 8.8. Disease Surveillance Diagnostics
- 8.9. Progression Tracking Diagnostics

9. BY DISEASE SEVERITY

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
 - 9.1.2. Market Attractiveness Index, By Disease Severity
- 9.2. MASLD*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

- 9.3. Early MASH
- 9.4. Mild Fibrosis
- 9.5. Moderate Fibrosis
- 9.6. Advanced Fibrosis
- 9.7. Severe Fibrosis
- 9.8. Cirrhosis Stage
- 9.9. High Risk Progression Population

10. BY END-USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Hepatology Clinics
- 10.4. Gastroenterology Clinics
- 10.5. Diagnostic Laboratories
- 10.6. Imaging Centers
- 10.7. Specialty Liver Centers
- 10.8. Academic Research Centers
- 10.9. Ambulatory Diagnostic Centers

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America*
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
 - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
 - 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
 - 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.8.1. U.S.

11.2.8.2. Canada

11.2.8.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User

11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.8.1. Germany

11.3.8.2. UK

11.3.8.3. France

11.3.8.4. Russia

11.3.8.5. Spain

11.3.8.6. Italy

11.3.8.7. Poland

11.3.8.8. Rest of Europe

11.4. Latin America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method

11.4.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose

11.4.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity

11.4.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User

11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.4.8.1. Brazil

11.4.8.2. Argentina

11.4.8.3. Rest of Latin America

11.5. Asia-Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow

11.5.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method

11.5.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose

11.5.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity

11.5.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User

11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.5.8.1. China

11.5.8.2. India

11.5.8.3. Japan

11.5.8.4. Australia

11.5.8.5. South Korea

11.5.8.6. Indonesia

11.5.8.7. Malaysia

11.5.8.8. Rest of Asia-Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow

11.6.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity

11.6.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User

11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.6.8.1. UAE

11.6.8.2. Saudi Arabia

11.6.8.3. South Africa

11.6.8.4. Israel

11.6.8.5. Turkiye

11.6.8.6. Rest of Middle East and Africa

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario

12.2. Market Share Analysis - Global

12.3. Market Share Analysis - North America

12.4. Market Share Analysis - Europe

12.5. Market Share Analysis - Asia-Pacific

12.6. Mergers and Acquisitions Analysis

12.7. Partner Identification Analysis

12.8. Investment & Funding Landscape

12.9. Strategic Alliances & Innovation Pipeline

13. COMPANY PROFILES

13.1. Echosens*

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Revenue Analysis

13.1.4. Pricing Analysis

13.1.5. SWOT Analysis

13.1.6. Recent Developments

13.1.6.1. Major Deals

13.1.6.2. M&A

13.1.6.3. Collaboration

13.1.6.4. Acquisition

13.1.6.5. Joint Ventures

13.1.6.6. Innovations

13.1.7. Recent News

13.1.7.1. Events

13.1.7.2. Conferences

13.1.7.3. Symposiums

13.1.7.4. Webinars

13.2. Siemens Healthineers AG

13.3. Perspectum Limited

13.4. Nordic Bioscience

13.5. BioPredictive

13.6. Rubi? Metabolomics

13.7. PathAI, Inc.

13.8. Histoindex Pte Ltd.

13.9. F. Hoffmann-La Roche Ltd.

13.10. GE HealthCare

13.11. Koninklijke Philips N.V. LIST NOT EXHAUSTIVE

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: MASH Diagnostics Market - 2026-2035

Product link: <https://marketpublishers.com/r/M94505329AB4EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M94505329AB4EN.html>